Potential adverse effects of negative publicity surrounding antivirals for influenza

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Dunning, Jake ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADVERSE OUTCOME; ANTIVIRAL THERAPY; DRUG EFFICACY; HUMAN; INFLUENZA; INFORMATION DISSEMINATION; LETTER; MASS MEDIUM; MEDICAL INFORMATION; MORTALITY; PANDEMIC; PRIORITY JOURNAL; PUBLIC HEALTH;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA, HUMAN;

EID: 84899629611     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3015     Document Type: Letter

References (4)

1. Health Protection Agency. Surveillance of influenza and other respiratory viruses in the UK: 2010-11 report. www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/ 1296687414154.
2. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014;4:CD008965
3. Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. BMJ 2014;348:g2263. (10 April.)
4. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TSA, Al Mamun A, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; published online 19 Mar.